Key result
Circulating fibrosis biomarkers complement imaging for myocardial remodeling but lack outcome validation to guide revascularization.
Why the study?
In patients with chronic total occlusion on coronary angiography, non-invasive myocardial viability assessment guides revascularization but is often limited by myocardial fibrosis.
Do circulating fibrosis biomarkers and non-invasive imaging improve myocardial viability assessment in patients with chronic total occlusion?
Do circulating fibrosis biomarkers and non-invasive imaging improve myocardial viability assessment in patients with chronic total occlusion?
Circulating fibrosis biomarkers show potential to complement imaging in assessing myocardial viability in CTO patients, but require standardization and large-scale validation before clinical implementation.
Answers are grounded in this paper and cite their sources.
Fibrosis limits current viability tests in CTO; leaves optimal non-invasive strategy open for prospective validation.
In patients with chronic total occlusion on coronary angiography, myocardial viability assessment is an essential tool in guiding treatment decisions, especially revascularization.Current non-invasive tests are often limited by the presence of myocardial fibrosis.This narrative review incorporates evidence from 76 studies and aims to provide an updated overview of non-invasive methods for myocardial viability assessment, with emphasis on the role of myocardial fibrosis.Every imaging modality provides valuable information, even though they differ in sensitivity, specificity, availability, radiation exposure, contraindications and limitations in the presence of fibrosis.Biomarkers that provide insight into different aspects of myocardial fibrosis -including collagen synthesis (procollagen type I carboxy-terminal propeptide and procollagen type III amino-terminal propeptide), as well as inflammation and fibrotic signalling (galectin-3) -may complement imaging by reflecting myocardial remodelling.However, main limitations to this approach are no standardized reference ranges and cut-off values, analytical variability and insufficient validation for clinical outcomes prediction.Despite their potential to guide personalized revascularization decisions, circulating fibrosis biomarkers currently remain experimental tools.Further large-scale prospective clinical studies that incorporate biomarkers with imaging are needed before their implementation into clinical practice.
No takes yet. Share an insight, caveat, or question.
Tomašić et al. (2026) conducted a review in Chronic total occlusion and myocardial fibrosis (n=76). Circulating fibrosis biomarkers (PICP, PIIINP, Gal-3) and non-invasive imaging was evaluated. Circulating fibrosis biomarkers such as PICP, PIIINP, and Gal-3 reflect myocardial remodeling and may complement imaging, but currently lack outcome-based validation to guide revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: